Andreas Vilhelmsson holds a Ph.D. in public health and works as a researcher and public health consultant with a broad interest in different aspects of human health, with a special focus on issues concerning global health, environmental health, climate change, mental health, pharmaceuticals (regulation, toxicology, and pharmacovigilance), pandemics, nudging, AI and digitalization.
Currently, he is working as a research assistant in a research project at the Division of Occupational and Environmental Medicine, Lund University looking at different environmental exposures and risk of cerebral pares. He is also involved in a project looking at how nudging techniques can be used within a clinical setting to change behavior.
Most importantly, he is currently working on a book on climate change and health that can be used within different courses in medicine, public health, sociology, and public policy. He also edits and writes for a Swedish climate and environmental blog.
Olofsson T, Vilhelmsson A, Hedlund M, Knaggård Å, Mulinari S. (2021). Comparative Covid Response: Crisis, Knowledge, Politics. Jasanoff S, Hilgartner S, Hurlbut, JB, Özgöde O, Rayzberg M. (eds.). 4 p
Mulinari S, Vilhelmsson A, Rickard E, Ozieranski P. (2020). “Five years of pharmaceutical industry funding of patient organisations in Sweden: cross sectional study of companies, patient organisations and drugs,” PLOS ONE; 15(6), June 24, 2020.
Vilhelmsson A, Mulinari M. (2020). “Pharmaceutical lobbying and pandemic stockpiling: A feeling of déjà vu in the Nordic countries and why the sociological perspective is crucial to understand COVID-19.” Acta Sociologica; 63(4), October 8, 2020.
Vilhelmsson A, Mulinari S*. (2018). “Pharmaceutical lobbying and pandemic stockpiling of Tamiflu: a qualitative study of arguments and tactics,“ Journal of Public Health; 40(3): 646–651, September 1, 2018.
Vilhelmsson A, Davis C, Mulinari S*. (2016). “Pharmaceutical industry off-label promotion and self-regulation: a document analysis of off-label promotion rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.” PLoS Medicine; 13(1), January 26, 2016.